NIH Pauses Eli Lilly COVID-19 Antibody Trial Due to ‘Safety Concerns’
The FDA classified problems in the late-stage clinical trial of Eli Lilly’s COVID-19 antibody treatment as the most serious level of violation …
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
